Profound Medical (PROF)
(Delayed Data from NSDQ)
$7.80 USD
-0.04 (-0.51%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.87 +0.07 (0.90%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Profound Medical falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 47 | 67 | 84 | 14 |
Receivables | 7 | 6 | 1 | 7 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 8 | 7 | 5 | 4 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 42 | 62 | 77 | 98 | 22 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 4 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 4 | 5 | 5 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 44 | 64 | 87 | 105 | 29 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 3 | 3 |
Current Portion Long-Term Debt | 2 | 1 | 0 | 0 | 4 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 6 | 4 | 4 | 5 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5 | 7 | 0 | 0 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 12 | 6 | 7 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 217 | 206 | 220 | 212 | 98 |
Capital Surplus | 20 | 19 | 17 | 11 | 15 |
Retained Earnings | -218 | -189 | -161 | -130 | -99 |
Other Equity | 12 | 17 | 5 | 5 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 31 | 52 | 81 | 97 | 14 |
Total Liabilities & Shareholder's Equity | 44 | 64 | 87 | 105 | 29 |
Total Common Equity | 31 | 52 | 81 | 97 | 14 |
Shares Outstanding | 24.40 | 20.80 | 20.70 | 20.20 | 15.20 |
Book Value Per Share | 1.28 | 2.50 | 3.89 | 4.82 | 0.93 |
Fiscal Year End for Profound Medical falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 34 | 41 | 26 | 34 | 39 |
Receivables | 7 | 7 | 7 | 7 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 7 | 7 | 7 | 8 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 48 | 56 | 42 | 48 | 55 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 1 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 50 | 57 | 44 | 50 | 57 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 2 | 6 | 2 | 2 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 6 | 10 | 6 | 5 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 4 | 0 | 5 | 5 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 12 | 13 | 12 | 12 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 231 | 233 | 217 | 213 | 216 |
Capital Surplus | 20 | 20 | 20 | 18 | 19 |
Retained Earnings | -231 | -224 | -218 | -209 | -203 |
Other Equity | 19 | 17 | 12 | 17 | 13 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 39 | 46 | 31 | 39 | 44 |
Total Liabilities & Shareholder's Equity | 50 | 57 | 44 | 50 | 57 |
Total Common Equity | 39 | 46 | 31 | 39 | 44 |
Shares Outstanding | 24.40 | 24.40 | 24.40 | 21.30 | 21.20 |
Book Value Per Share | 1.61 | 1.88 | 1.28 | 1.81 | 2.09 |